Beaver Bio Completes Tens of Millions of RMB Series B Financing to Advance Nanomagnetic Bead Technology and Files IPO Prospectus
VCBeat (WeChat ID: vcbeat) has recently learned that Suzhou Beaver Biomedical Engineering Co., Ltd. (hereinafter referred to as “Beaver Biomedical”), a leading enterprise in the field of magnetic nanobeads, has completed a Series B financing round worth tens of millions of yuan.This funding round was co-led by Boya Junzilan and Aowen Venture Capital, with participation from Shenzhen Huihe and Junzi Jing.。
Following the completion of its Series B financing, Suzhou Beaver Biomedical Engineering Co., Ltd. will further scale up the mass production of third-generation chemiluminescence and immunocapture magnetic beads, while advancing the in-depth development of advanced manufacturing technologies for fourth-generation nanomagnetic beads. Positioning itself for the global market, the company aims to establish an industrialization base for biomedical products centered on its core nanomagnetic bead technology, thereby comprehensively enhancing its capabilities in providing fully automated solutions for the entire workflow of clinical and non-clinical biosample processing.
BeaverBeads®SEM Imaging
Beaver Biomedical Engineering (BEAVER), founded in late 2011 and headquartered in Suzhou Industrial Park, is a national high-tech enterprise that was among the earliest in China to engage in the research and development of magnetic nanoparticle technologies and products. Over the past decade, Beaver has focused on the independent R&D of magnetic nanoparticle technologies, achieving continuous technological breakthroughs and industrial upgrades—from its first-generation dispersed-structure magnetic nanoparticles, through second-generation core-shell silica-coated magnetic beads, to third-generation multi-layered polymer magnetic beads.
Currently, Beaver Biomedical has completed the construction of an industrialization base spanning nearly 6,000 square meters. Targeting the biomedical research and in vitro diagnostics (IVD) industries, the company has successively launched more than twenty product series, including protein purification magnetic beads, nucleic acid extraction magnetic beads, chemiluminescence and immunocapture magnetic beads, as well as supporting biological reagents, consumables, and automated equipment for the entire workflow of biological sample collection, preservation, and extraction.
BeaverBeads®Biological Applications
Dr. Ren Hui, Chairman and CEO of Suzhou Beaver Biomedical Engineering Co., Ltd.Introduction: "Nanobead technology is suitable for automated and high-throughput sample processing, such as the efficient extraction of cell-free extracellular nucleic acids and the labeled capture of ultra-trace and trace biological macromolecules. It has been widely applied in fields including Down syndrome screening, molecular and immunological detection of tumors, and cellular immunotherapy. Currently, over 90% of product varieties rely on imports, earning it the reputation as 'chip-level' raw materials in the biomedical field."
Beaver has accumulated nearly a decade of expertise in “third-generation” magnetic nanoparticle bead technology. Benefiting from the widespread demand for high-throughput sample processing using magnetic bead-based methods during the COVID-19 pandemic, the Beaver team has significantly strengthened its capabilities and depth. We have appointed Dr. Huang Mingxian, a nationally distinguished expert in materials science, as our Chief Scientist, and Ms. Liang Ping, a successful entrepreneur, as Vice President of Marketing. Currently, we are establishing a research and development center spanning over 3,000 square meters, with substantial investments in raw material technologies and biomedical application products. Beaver’s goal is not merely to replace imported products with domestic brands; the greater challenge lies in gaining recognition in the international market.
Co-lead investors in the investment of Suzhou Beaver Biomedical Engineering Co., Ltd.Wang Xuejun, Founding Partner of Junzilan Capital“He established a dual-drive technology strategy from the very inception of Beaver Biomedical, focusing on the two core fields of nanotechnology and biotechnology to create comprehensive solutions for biosample processing. Dr. Ren Hui has deeply cultivated the field of magnetic beads, and his down-to-earth and pragmatic style aligns perfectly with Junzilan Capital’s value proposition of ‘Gentlemen as Orchids, Aiming High.’ Furthermore, as Junzilan Capital manages the Suzhou Peking University Alumni Association Fund, and Dr. Ren is an outstanding entrepreneur within the Suzhou Peking University Alumni Association, he represents the high-quality partner we have long sought. We look forward to supporting Beaver Biomedical in continuously refining and innovating its underlying nanomagnetic bead technologies and applications, bringing disruptive medical technology products to the market.”
Co-Lead InvestorDr. Zhou Min, Managing Partner at Aowen Venture CapitalIt also acknowledged: “Ao Wen is optimistic about the development trends and growth potential of the IVD industry in China. As a leading domestic supplier of upstream core materials, Suzhou Beaver Biomedical Engineering Co., Ltd. (Beaver Biomedical) will benefit from two major trends: the booming local IVD industry and the localization of international brands. Furthermore, building on years of technological accumulation, along with an expanding product portfolio and the development of next-generation magnetically activated bead production technologies with international leadership, Beaver’s products will become more competitive in the global market. We look forward to Beaver Biomedical ultimately becoming a top-tier international brand in the field of magnetic beads.”
Co-investorMr. Chen Xiangyong, Chairman of Shenzhen Huihe Assets“It holds that ‘Suzhou Beaver, as a biotechnology enterprise with profound technical expertise and an international business perspective, not only sets ambitious goals and dares to challenge top global peers, but also remains grounded, pursues steady progress, and continuously achieves phased R&D and operational results, thereby aligning with the investment philosophy and criteria of Huihe Asset. We believe that Suzhou Beaver’s continuously iterated and innovative magnetic nanobead technology will enjoy broad application prospects in the future.’”
Junzilan Capital was established in January 2015 as an emerging professional investment firm headquartered in Suzhou. With assets under management exceeding RMB 1 billion, the firm focuses on healthcare, new materials, semiconductors, and other sectors. The Boya Junzilan Fund, managed by Junzilan Capital, serves as the fund for the Suzhou Peking University Entrepreneurs Chamber of Commerce. It primarily invests in high-quality startups founded by Peking University alumni, targeting strategic emerging industries including but not limited to biopharmaceuticals, medical devices, new materials, and intelligent manufacturing. Its Expert Advisory Committee comprises six chairmen of listed companies and several renowned entrepreneurs, all of whom are Peking University alumni. The Junzijing Fund is a technology-focused fund created by Junzilan Capital in collaboration with provincial, municipal, and district-level governments. It prioritizes strategic emerging fields such as new material technologies, intelligent manufacturing technologies, and the Internet of Things (IoT), with a key focus on early-stage and growth-stage projects.
Aowen Venture Capital is a strategic investment fund with deep industrial expertise, focused on investing in hard-tech companies that drive industrial transformation. Aowen Venture Capital believes that innovation in hard technology is key to making the economy more efficient, companies more sustainable, and living environments healthier. Its portfolio companies in the hard-tech sector are distributed globally, from Asia to North America and Europe, focusing on the development of advanced materials and manufacturing processes, industrial digitalization, artificial intelligence and IoT solutions, clean energy, as well as technologies and products that accelerate carbon neutrality. Aowen’s venture capital fund is supported by financial and strategic investors, including BASF, British American Tobacco, General Electric, Heraeus, Henkel, Petronas, SABIC, and Samsung. Aowen’s portfolio companies are making a significant impact across various industries such as 5G, the circular economy, hydrogen energy, consumer electronics, smart cities, and digital industry.
Shenzhen Huihe is an asset management firm specializing in equity investment, with all its partners possessing extensive practical experience in long-term industrial enterprise operations or asset management. The company adopts a boutique investment strategy, selecting investment targets with high standards, and seeks long-term, stable appreciation of assets under the premise of strictly controlling investment risks.